BR112016000804A2 - Método para tratar hemorragia, choque e lesão cerebral - Google Patents
Método para tratar hemorragia, choque e lesão cerebralInfo
- Publication number
- BR112016000804A2 BR112016000804A2 BR112016000804A BR112016000804A BR112016000804A2 BR 112016000804 A2 BR112016000804 A2 BR 112016000804A2 BR 112016000804 A BR112016000804 A BR 112016000804A BR 112016000804 A BR112016000804 A BR 112016000804A BR 112016000804 A2 BR112016000804 A2 BR 112016000804A2
- Authority
- BR
- Brazil
- Prior art keywords
- shock
- brain injury
- treat hemorrhage
- potassium channel
- hemorrhage
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
MÉTODO PARA TRATAR HEMORRAGIA, CHOQUE E LESÃO CEREBRAL. Trata-se de uma composição e um método para aumentar a pressão sanguínea, que inclui um estado de pouca dor ou analgésico, ou anestesia hipotensiva em um indivíduo que sofreu um choque ou hipotensão com risco de vida, ou reduzir a hipoperfusão no corpo inteiro de um indivíduo. A composição compreende (i) um composto selecionado a partir de pelo menos um dentre um abridor de canal de potássio, um agonista de canal de potássio e um agonista de receptor de adenosina; e (ii) um agente antiarrítmico ou um anestésico local.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2013902658A AU2013902658A0 (en) | 2013-07-17 | A method for reducing inflammation, coagulation and adhesions | |
AU2013902659A AU2013902659A0 (en) | 2013-07-17 | A method for treating haemorrhage, shock and brain injury | |
AU2013902657A AU2013902657A0 (en) | 2013-07-17 | A method for reducing infection, sepsis and injury | |
AU2013902656A AU2013902656A0 (en) | 2013-07-17 | A method for inducing whole body arrest | |
AU2013903644A AU2013903644A0 (en) | 2013-09-23 | A method for organ arrest, protection and preservation and reducing tissue injury | |
PCT/AU2014/050130 WO2015006828A1 (en) | 2013-07-17 | 2014-07-17 | A method for treating haemorrhage, shock and brain injury |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112016000804A2 true BR112016000804A2 (pt) | 2017-08-22 |
Family
ID=52345629
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112016000804A BR112016000804A2 (pt) | 2013-07-17 | 2014-07-17 | Método para tratar hemorragia, choque e lesão cerebral |
BR112016000809A BR112016000809A2 (pt) | 2013-07-17 | 2014-07-17 | Método para tratar infecção, sepsia e lesão |
BR112016000898A BR112016000898A2 (pt) | 2013-07-17 | 2014-07-17 | Método para parada, proteção e preservação de órgão e redução de lesão de tecido |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112016000809A BR112016000809A2 (pt) | 2013-07-17 | 2014-07-17 | Método para tratar infecção, sepsia e lesão |
BR112016000898A BR112016000898A2 (pt) | 2013-07-17 | 2014-07-17 | Método para parada, proteção e preservação de órgão e redução de lesão de tecido |
Country Status (8)
Country | Link |
---|---|
US (3) | US20160158280A1 (pt) |
EP (3) | EP3021856B1 (pt) |
CN (3) | CN105722516A (pt) |
AU (3) | AU2014292825A1 (pt) |
BR (3) | BR112016000804A2 (pt) |
CA (3) | CA2917653A1 (pt) |
MX (3) | MX2016000649A (pt) |
WO (5) | WO2015006830A1 (pt) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011133736A2 (en) | 2010-04-21 | 2011-10-27 | The Regents Of The University Of Michigan | Fluoroscopy-independent, endovascular aortic occlusion system |
US9474882B2 (en) | 2013-02-26 | 2016-10-25 | Prytime Medical Devices, Inc. | Fluoroscopy-independent balloon guided occlusion catheter and methods |
JP6343009B2 (ja) | 2013-09-09 | 2018-06-13 | プリタイム・メディカル・デバイシーズ・インコーポレイテッドPrytime Medical Devices,Inc. | 低輪郭閉塞カテーテル |
US10232142B2 (en) | 2014-06-10 | 2019-03-19 | Prytime Medical Devices, Inc. | Conduit guiding tip |
US9925233B2 (en) | 2015-01-30 | 2018-03-27 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
AU2016232781B2 (en) | 2015-03-19 | 2017-11-02 | Prytime Medical Devices, Inc. | System for low-profile occlusion balloon catheter |
CA3003156C (en) | 2015-11-06 | 2023-12-05 | Terry Vanden Hoek | Peptides and method for treatment of cardiac arrest |
WO2017137528A1 (en) * | 2016-02-12 | 2017-08-17 | Charité - Universitätsmedizin Berlin | Adenosine a1 receptor agonist for use in treatment of status epilepticus |
EP4302815A3 (en) | 2016-06-02 | 2024-03-27 | Prytime Medical Devices, Inc. | System and method for low-profile occlusion ballon catheter |
US10707531B1 (en) | 2016-09-27 | 2020-07-07 | New Dominion Enterprises Inc. | All-inorganic solvents for electrolytes |
CA3049539C (en) | 2017-01-12 | 2022-09-20 | The Regents Of The University Of California | Endovascular perfusion augmentation for critical care |
WO2018195507A1 (en) | 2017-04-21 | 2018-10-25 | The Regents Of The University Of California | Aortic flow meter and pump for partial-aortic occlusion |
EP4233989A3 (en) | 2017-06-07 | 2023-10-11 | Shifamed Holdings, LLC | Intravascular fluid movement devices, systems, and methods of use |
EP3710076B1 (en) | 2017-11-13 | 2023-12-27 | Shifamed Holdings, LLC | Intravascular fluid movement devices, systems, and methods of use |
CN111670002A (zh) * | 2017-12-05 | 2020-09-15 | 神经索引公司 | 麻醉管理的系统及方法 |
EP4085965A1 (en) | 2018-02-01 | 2022-11-09 | Shifamed Holdings, LLC | Intravascular blood pumps and methods of use and manufacture |
CN108753683B (zh) * | 2018-05-26 | 2022-02-15 | 温州医科大学 | 一种促进冻存组织器官和细胞活性复苏的溶液体系 |
US20210321954A1 (en) * | 2018-08-31 | 2021-10-21 | Louisiana Tech Research Corporation | System and method for network analysis of a patient's neuro cardio-respiratory-system |
CN110352951A (zh) * | 2018-11-15 | 2019-10-22 | 崔磊 | 一种无血清无dmso组织工程骨冻存液及其制备和冻存方法 |
CN109248173A (zh) * | 2018-11-23 | 2019-01-22 | 浙江省人民医院 | 一种心脏停搏液 |
CN113795247B (zh) * | 2018-12-14 | 2024-04-05 | 陈益祥 | 用于心脏手术的稳定心脏麻痹液 |
CA3124766A1 (en) * | 2019-01-10 | 2020-07-16 | Organ Assist B.V. | An apparatus and a method for ex-vivo measurement of performance of a donor heart |
US20220175823A1 (en) * | 2019-03-29 | 2022-06-09 | Virginia Commonwealth University | Polymer agents for cardiopulmonary resuscitation |
CN110057821B (zh) * | 2019-04-16 | 2021-09-07 | 上海交通大学 | 用于人类配子快速冻融过程观测的低温显微成像系统 |
US20220317135A1 (en) * | 2019-04-30 | 2022-10-06 | University Of Florida Research Foundation, Inc. | Biomarker panel for sepsis encephalopathy |
WO2021011473A1 (en) | 2019-07-12 | 2021-01-21 | Shifamed Holdings, Llc | Intravascular blood pumps and methods of manufacture and use |
WO2021016372A1 (en) | 2019-07-22 | 2021-01-28 | Shifamed Holdings, Llc | Intravascular blood pumps with struts and methods of use and manufacture |
WO2021051064A1 (en) * | 2019-09-12 | 2021-03-18 | The General Hospital Corporation | System and method for determining treatment outcomes for neurological disorders based on functional connectivity parameters |
KR20220072853A (ko) * | 2019-09-24 | 2022-06-02 | 퍼넘브러, 인코퍼레이티드 | 주입 카테터 및 사용 방법들 |
WO2021062265A1 (en) | 2019-09-25 | 2021-04-01 | Shifamed Holdings, Llc | Intravascular blood pump systems and methods of use and control thereof |
CN110692580B (zh) * | 2019-11-15 | 2021-11-02 | 苑春亭 | 一种刺参度夏池塘及安全通过夏眠的方法 |
CN113134116B (zh) * | 2020-01-20 | 2022-09-06 | 山东威高宏瑞医学科技有限公司 | 内镜微创手术用的填充组合物及填充制剂 |
WO2021188602A2 (en) | 2020-03-16 | 2021-09-23 | Certus Critical Care, Inc. | Blood flow control devices, systems, and methods and error detection thereof |
CN111407244A (zh) * | 2020-03-30 | 2020-07-14 | 上海大学 | 基于svr算法的左心室收缩末期弹性预测方法及系统 |
CN111345293B (zh) * | 2020-04-08 | 2021-08-27 | 江门海关技术中心 | 一种虫类标本用防蛀剂及其制备方法 |
CN111937861B (zh) * | 2020-08-17 | 2021-10-26 | 南昌大学第二附属医院 | 一种七氟烷缺血再灌注装置及使用方法 |
CN112195151B (zh) * | 2020-10-28 | 2022-06-21 | 范德里希(上海)生物科技有限公司 | 一种牙髓间充质干细胞复苏培养液、制备方法及复苏培养方法 |
CN112826463B (zh) * | 2020-12-31 | 2023-11-10 | 苏州爱琴生物医疗电子有限公司 | 一种血压调控范围的确定装置和相关设备 |
AU2022239617A1 (en) * | 2021-03-18 | 2023-09-28 | Washington University | Hemodilution detector |
CN113854280B (zh) * | 2021-09-06 | 2022-05-31 | 创芯国际生物科技(广州)有限公司 | 一种低温保存液及其制备方法和应用 |
WO2023154844A2 (en) * | 2022-02-10 | 2023-08-17 | Workman David Henry | Compositions comprising nad+ and associated methods of treatment |
WO2023245103A2 (en) * | 2022-06-15 | 2023-12-21 | Vascular Perfusion Solutions, Inc. | Tissue perfusion and viability sensing system |
WO2024050139A1 (en) * | 2022-09-02 | 2024-03-07 | AnaBios Corporation | Therapeutic uses of cardiac myosin inhibitors |
Family Cites Families (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3795581A (en) * | 1971-11-01 | 1974-03-05 | American Hospital Supply Corp | Method of maintaining or restoring the 2,3-diphosphoglycerate content of human red cells |
US4112070A (en) * | 1977-06-08 | 1978-09-05 | Research Corporation | Blood preservation system |
SU878297A1 (ru) | 1978-05-03 | 1981-11-07 | Научно-Исследовательский Институт Трансплантологии И Искусственных Органов | Состав дл сохранени жизнеспособности оперируемого сердца |
US4798824A (en) | 1985-10-03 | 1989-01-17 | Wisconsin Alumni Research Foundation | Perfusate for the preservation of organs |
US5006512A (en) | 1987-10-02 | 1991-04-09 | Tsuyoshi Ohnishi | Therapeutic usages of inhibitors for a potassium efflux channel |
US4968675A (en) * | 1988-10-28 | 1990-11-06 | Upjohn | Non-hemolytic lazaroid parenteral formulation |
US5256770A (en) | 1990-04-09 | 1993-10-26 | Schering Ag | Oxidation resistant thrombomodulin analogs |
DE3926287A1 (de) | 1989-08-09 | 1991-02-21 | Bernhard Clasbrummel | Medizinische anwendung von omega-conotoxin gvia oder omega-conotoxin gvia-analoga zur sympathikolyse |
US5145771A (en) | 1990-04-12 | 1992-09-08 | The University Of North Carolina At Chapel Hill | Rinse solution for organs and tissues |
US5206222A (en) | 1991-05-22 | 1993-04-27 | Vanderbilt University | Methods for the reduction of myocardial reperfusion injury |
US5407793A (en) | 1991-10-18 | 1995-04-18 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | An aqueous heart preservation and cardioplegia solution |
RU2025973C1 (ru) | 1992-02-10 | 1995-01-09 | Научно-производственное предприятие "Биофарм" | Раствор для консервации живых органов |
US5370989A (en) | 1992-04-03 | 1994-12-06 | The Trustees Of Columbia University In The City Of New York | Solution for prolonged organ preservation |
US5405742A (en) * | 1993-07-16 | 1995-04-11 | Cyromedical Sciences, Inc. | Solutions for tissue preservation and bloodless surgery and methods using same |
CN1151685A (zh) * | 1994-05-25 | 1997-06-11 | 杰丽·I·雅各布森 | 改善衰老过程的方法和设备 |
US5679706A (en) | 1994-09-30 | 1997-10-21 | Bristol-Myers Squibb Company | Combination of a potassium channel activator and an antiarrhythmic agent |
US5554497A (en) | 1994-12-12 | 1996-09-10 | Charlotte-Mecklenburg Hospital Authority | Cardioplegic solution for arresting an organ |
US5656420A (en) | 1995-02-24 | 1997-08-12 | University Of Kentucky Research Foundation | Method for employing the delta opioid dadle to extend tissue survival time during ischemia |
WO1997016169A1 (en) * | 1995-11-01 | 1997-05-09 | Chiron Corporation | Treatment of a cardiovascular indication by delivery of therapeutics to the pericardial space |
JP3875295B2 (ja) | 1995-11-30 | 2007-01-31 | 功 竹内 | 心筋保護液 |
US5939394A (en) * | 1996-01-18 | 1999-08-17 | Fleming & Company | Methods and compositions for the prevention and treatment of immunological disorders, inflammatory diseases and infections |
US6043224A (en) | 1996-09-05 | 2000-03-28 | The Massachusetts Institute Of Technology | Compositions and methods for treatment of neurological disorders and neurodegenerative diseases |
IT1297886B1 (it) | 1997-02-28 | 1999-12-20 | Carmine Antropoli | Nifedipina per uso topico |
AU740770B2 (en) | 1997-06-18 | 2001-11-15 | Aderis Pharmaceuticals, Inc. | Compositions and methods for preventing restenosis following revascularization procedures |
CN1057192C (zh) | 1997-09-10 | 2000-10-11 | 上海长征医院 | 一种配制多器官保存液的方法 |
US6011017A (en) | 1998-04-15 | 2000-01-04 | Cypros Pharmaceutical Corp. | Method of reducing pulmonary hypertension and atrial fibrillation after surgery using cardiopulmonary bypass |
CN1309562A (zh) | 1998-07-16 | 2001-08-22 | 纪念斯隆-凯特林癌症中心 | 包括一种阿片样物质镇痛剂和一种nmda拮抗剂的局部给药组合物 |
ES2435847T3 (es) | 1998-10-23 | 2013-12-23 | Polyheal Ltd. | Composiciones de microesferas para curar heridas |
US6358208B1 (en) | 1998-11-21 | 2002-03-19 | Philipp Lang | Assessment of cardiovascular performance using ultrasound methods and devices that interrogate interstitial fluid |
BR0010653A (pt) | 1999-03-23 | 2002-02-05 | Univ James Cook | Parada, proteção e preservação de orgãos |
US6586413B2 (en) | 1999-11-05 | 2003-07-01 | The United States Of America As Represented By The Department Of Health And Human Services | Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists |
GB9930079D0 (en) * | 1999-12-20 | 2000-02-09 | Glaxo Group Ltd | Medicaments |
WO2001054679A2 (en) | 2000-01-27 | 2001-08-02 | Children's Hospital Research Foundation | Transdermal composition containing an anesthetic and a vasodilator agent |
JP2001261575A (ja) | 2000-03-13 | 2001-09-26 | General Hospital Corp | 血管収縮を調節する方法とその組成物 |
US6569615B1 (en) | 2000-04-10 | 2003-05-27 | The United States Of America As Represented By The Department Of Veteran's Affairs | Composition and methods for tissue preservation |
JP2004512260A (ja) | 2000-04-28 | 2004-04-22 | メモリアル スローン−ケッタリング キャンサー センター | 局所麻酔/オピオイド製剤およびその使用方法 |
US6271228B1 (en) | 2000-04-28 | 2001-08-07 | Pfizer Inc. | Blood pressure stabilization during hemodialysis |
ATE332668T1 (de) | 2000-09-26 | 2006-08-15 | Medtronic Inc | Medizinische vorrichtung zur blutstromsteuerung |
US20030224343A1 (en) | 2002-01-29 | 2003-12-04 | University Of Utah Research Foundation | Kappa-PVIIA-related conotoxins as organ protectants |
CA2379211A1 (fr) | 2002-03-28 | 2003-09-28 | Institut De Cardiologie De Montreal | Utilisation du bleu de methylene pour renverser la reaction hemodynamique exageree induite par la combinaison d'un derive nitre et du sildenafil ou d'une molecule de meme classe (inhibiteur de la phosphodiesterase) |
CN1646142A (zh) | 2002-04-18 | 2005-07-27 | Cv医药有限公司 | 包括给予A1腺苷激动剂以及β受体阻滞剂、钙通道阻滞剂、或强心苷的治疗心律失常的方法 |
AUPS312602A0 (en) | 2002-06-21 | 2002-07-18 | James Cook University | Organ arrest, protection, preservation and recovery |
US20040229780A1 (en) | 2002-09-20 | 2004-11-18 | Olivera Baldomero M. | KappaM-conopeptides as organ protectants |
US6921633B2 (en) | 2002-11-18 | 2005-07-26 | Biolife Solutions Incorporated | Methods and compositions for the preservation of cells, tissues or organs in the vitreous state |
US20040167226A1 (en) | 2002-12-16 | 2004-08-26 | Serafini Tito A. | Methods for the treatment of pain and traumatic injury using benzamides and compositions containing the same |
GB2436255B (en) | 2002-12-23 | 2007-11-28 | Global Cardiac Solutions Pty L | Organ preconditioning, arrest, protection, preservation and recovery |
GB2412067B (en) | 2002-12-23 | 2007-11-14 | Global Cardiac Solutions Pty L | Organ preconditioning, arrest, protection, preservation and recovery (2) |
US6992075B2 (en) | 2003-04-04 | 2006-01-31 | Barr Laboratories, Inc. | C(14) estrogenic compounds |
AU2004245484A1 (en) | 2003-06-02 | 2004-12-16 | Georgetown University | Neuroprotective benzoate and benzamide compounds |
US7049309B2 (en) | 2003-10-14 | 2006-05-23 | Bristol-Myers Squibb Company | 3-Thia-4-arylquinolin-2-one potassium channel modulators |
JP2008525468A (ja) | 2004-12-22 | 2008-07-17 | エモリー・ユニバーシティ | ポストコンディショニング臓器保護作用を増強する治療補助薬 |
WO2007030198A2 (en) | 2005-07-11 | 2007-03-15 | Human Biosystems | Improved methods and solutions for storing donor organs |
CN101500409A (zh) * | 2006-05-29 | 2009-08-05 | 低温药理有限公司 | 改善的组织维持 |
EP2079301B1 (en) * | 2006-05-29 | 2017-03-15 | Hibernation Therapeutics, a KF LLC | Improved tissue maintenance |
US20130122108A1 (en) * | 2006-06-06 | 2013-05-16 | Robert G Matheny | Compositions for Regenerating Defective or Absent Myocardium |
ES2539762T3 (es) * | 2006-07-25 | 2015-07-03 | Hibernation Therapeutics, A Kf Llc | Tratamiento de traumatismos |
ES2683851T3 (es) * | 2006-10-06 | 2018-09-28 | Newsouth Innovations Pty Limited | Formación de partículas |
AU2008222595B2 (en) * | 2007-03-02 | 2014-03-27 | Hibernation Therapeutics, A Kf Llc | Transplants |
CN100423638C (zh) | 2007-03-22 | 2008-10-08 | 南京吉脉生物技术有限公司 | 一种器官保存液及其制备方法 |
CN101808509A (zh) * | 2007-07-25 | 2010-08-18 | 低温药理有限公司 | 改进的器官保护、维护和康复 |
CN101496512A (zh) * | 2008-02-01 | 2009-08-05 | 扬子江药业集团上海海尼药业有限公司 | 一种器官保存液及其制备方法 |
US20090198145A1 (en) * | 2008-02-06 | 2009-08-06 | Chow Harrison | Compositions, methods, and systems for rapid induction and maintenance of continuous rem sleep |
US20120258926A1 (en) | 2009-12-15 | 2012-10-11 | Valentyn Antochshuk | Formulations of acadesine |
CN102726366B (zh) | 2011-04-07 | 2014-06-04 | 中国人民解放军第二军医大学 | 一种器官保存液及其配制方法 |
-
2014
- 2014-07-17 WO PCT/AU2014/050132 patent/WO2015006830A1/en active Application Filing
- 2014-07-17 CA CA2917653A patent/CA2917653A1/en not_active Abandoned
- 2014-07-17 CA CA2917645A patent/CA2917645C/en active Active
- 2014-07-17 MX MX2016000649A patent/MX2016000649A/es unknown
- 2014-07-17 WO PCT/AU2014/050131 patent/WO2015006829A1/en active Application Filing
- 2014-07-17 CA CA2917629A patent/CA2917629A1/en not_active Abandoned
- 2014-07-17 AU AU2014292825A patent/AU2014292825A1/en not_active Abandoned
- 2014-07-17 MX MX2016000650A patent/MX2016000650A/es unknown
- 2014-07-17 EP EP14827107.5A patent/EP3021856B1/en active Active
- 2014-07-17 EP EP14825914.6A patent/EP3021854A4/en not_active Withdrawn
- 2014-07-17 BR BR112016000804A patent/BR112016000804A2/pt not_active Application Discontinuation
- 2014-07-17 BR BR112016000809A patent/BR112016000809A2/pt not_active Application Discontinuation
- 2014-07-17 WO PCT/AU2014/050128 patent/WO2015006827A1/en active Application Filing
- 2014-07-17 MX MX2016000651A patent/MX2016000651A/es unknown
- 2014-07-17 US US14/905,722 patent/US20160158280A1/en not_active Abandoned
- 2014-07-17 AU AU2014292827A patent/AU2014292827A1/en not_active Abandoned
- 2014-07-17 WO PCT/AU2014/050133 patent/WO2015006831A1/en active Application Filing
- 2014-07-17 AU AU2014292826A patent/AU2014292826A1/en not_active Abandoned
- 2014-07-17 WO PCT/AU2014/050130 patent/WO2015006828A1/en active Application Filing
- 2014-07-17 CN CN201480050992.7A patent/CN105722516A/zh active Pending
- 2014-07-17 EP EP14826665.3A patent/EP3021855A4/en not_active Withdrawn
- 2014-07-17 CN CN201480051003.6A patent/CN105579045A/zh active Pending
- 2014-07-17 BR BR112016000898A patent/BR112016000898A2/pt not_active Application Discontinuation
- 2014-07-17 CN CN201480051011.0A patent/CN105705151A/zh active Pending
- 2014-07-17 US US14/905,725 patent/US20160166598A1/en not_active Abandoned
-
2016
- 2016-01-19 US US15/000,727 patent/US10786525B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112016000804A2 (pt) | Método para tratar hemorragia, choque e lesão cerebral | |
BR112018069251A2 (pt) | métodos de intervenção precoce para prevenir ou melhorar a toxicidade | |
MX2020004948A (es) | Receptor de antígeno quimérico que selecciona como diana bcma, receptor de antígeno quimérico que selecciona como diana cd19 y terapias de combinación. | |
BR112012005225B8 (pt) | Uso de uma proteína de fusão actriib-fc para o tratamento de um transtorno relacionado ao osso ou associado à perda de músculo por crescimento muscular insuficiente | |
BR112015021371A2 (pt) | uso de agonistas de receptor de formil peptídeo 2 para tratar doenças inflamatórias oculares | |
BR112015022465A2 (pt) | método para tratamento não-tóxico para síndrome de abstinência de drogas | |
SG10201811841UA (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
MX2015002292A (es) | Metodos para tratar o prevenir asma administrando un antagonista de il-4r. | |
PE20180260A1 (es) | Metodos y kits para tratar la depresion | |
BR112016002171A2 (pt) | método, composição estéril e injetável e método para preparar uma composição estéril e injetável | |
BR112015012739A2 (pt) | sistemas e métodos de guia ortopédico | |
BR112015021392A2 (pt) | uso de agonistas do receptor de peptídeo formil 2 para tratar doenças dermatológicas | |
MX2018003893A (es) | Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos. | |
WO2015157559A3 (en) | 10',11'-modified saxitoxins useful for the treatment of pain | |
BR112013004685A2 (pt) | composição e método para reparação e regeneração muscular | |
BR112015024234A2 (pt) | composição de liberação sustentada injetável e método para o uso da mesma para tratar inflamação em articulações e dor associada com a mesma | |
BR112015004465A2 (pt) | sistemas, dispositivos e métodos para fornecer terapia com orientação de imagem | |
BR112015027440A2 (pt) | DERIVADO DE [1,2,4]TRIAZOL[4,3-a]PIRIDINA, MÉTODO DE PREPA-RAÇÃO OU APLICAÇÃO MÉDICA DO DERIVADO | |
BR112015013374A2 (pt) | dispositivo de luva hemostática e método para uso do mesmo | |
BR112015022650A8 (pt) | inibidores de quinase induzível por sal macrocíclico. | |
BR112014030279A2 (pt) | métodos para tratamento de neutropenia usando agonistas retinóide | |
BR112021021195A2 (pt) | Métodos para tratamento ou prevenção da asma pela administração de um antagonista de il-33 | |
BR112015010039A2 (pt) | tratamento de câncer com pomalidomida em um individuo com disfunção renal | |
BR112018014467A2 (pt) | tecnologia de sinergismo fármaco-anticorpo para o tratamento de doenças | |
BR112022020643A2 (pt) | Método de tratamento de esteato-hepatite não alcoólica |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |